SCHEMBL20356706

SCHEMBL20356706

Cc1nc(C(=O)O)nc(SC(C)C)c1Cc1ccccc1Cl

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ TP53 P04637 6/20 0.43
▸ MAPT P10636 4/20 0.43
▸ ALDH1A1 P00352 2/20 0.40
▸ LMNA P02545 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ HPGD P15428 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ ENPP1 P22413 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ P2RX7 Q99572 1/20 0.36
▸ POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL21526067 0.99 SMN1; SMN2 (0.44) SMN1; SMN2TP53MAPTALDH1A1LMNA
SCHEMBL20356703 0.87 SMN1; SMN2 (0.48) SMN1; SMN2TP53MAPTALDH1A1LMNA
SCHEMBL21526092 0.85 SMN1; SMN2 (0.56) SMN1; SMN2TP53MAPTALDH1A1LMNA
SCHEMBL21526045 0.81 SMN1; SMN2 (0.52) SMN1; SMN2TP53MAPTALDH1A1LMNA
SCHEMBL21526023 0.80 SMN1; SMN2 (0.51) SMN1; SMN2TP53MAPTALDH1A1LMNA
SCHEMBL21526041 0.79 SMN1; SMN2 (0.45) SMN1; SMN2TP53MAPTALDH1A1LMNA
SCHEMBL21526132 0.78 SMN1; SMN2 (0.49) SMN1; SMN2TP53MAPTALDH1A1LMNA
SCHEMBL21525997 0.78 SMN1; SMN2 (0.46) SMN1; SMN2TP53MAPTALDH1A1LMNA
SCHEMBL21525996 0.77 SMN1; SMN2 (0.48) SMN1; SMN2TP53MAPTALDH1A1LMNA
Hydrochloric Acid SCHEMBL21526118 0.77 SMN1; SMN2 (0.45) SMN1; SMN2TP53MAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3564216-B1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2021-10-27 — — EP disclosed
US-11034659-B2 Pyrimidine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-06-15 — — US disclosed
US-20200172494-A1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-06-04 — — US disclosed
EP-3564216-A1 PYRIMIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2019-11-06 — — EP disclosed
WO-2018124000-A1 PYRIMIDINE DERIVATIVE 第一三共株式会社 2018-07-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11034659-B2 Pyrimidine derivative GPR39, CFTR, TMEM109 SMN1; SMN2 2983/4885TP53 2921/4885MAPT 4880/4885
US-20200172494-A1 PYRIMIDINE DERIVATIVE GPR39, CFTR, TMEM109 SMN1; SMN2 2983/4885TP53 2921/4885MAPT 4880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback